Joshua Pinto - 17 Feb 2026 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: President
Issuer ticker: NMRA
Reported as of: 17 Feb 2026
Net transaction value: -$21,093
SEC form: 4
Accepted by SEC: 19 Feb 2026, 17:06:16 UTC
Prior SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto

Key filing fact

Joshua Pinto filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 19 Feb 2026.

Key facts

This page summarizes Joshua Pinto's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Feb 2026, 17:06.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001992595 Primary reporting owner

Relationship: President
Address: C/O NEUMORA THERAPEUTICS, INC., 260 ARSENAL WAY, SUITE 1, WATERTOWN
Signature: /s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto
Signature date: 19 Feb 2026

Shares, units, or other non-derivative securities reported in this filing.

NMRA transaction

Sale

NMRA holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Footnote F2

Shares held by Maple DE Holdings LLC.